IP Library Patent Application 11181661
Patent Application
App. No. 11/181,661

Mixed gas microbubble compositions

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/181,661
Abstract

A microbubble preparation formed of a plurality of microbubbles comprising a first gas and a second gas surrounded by a membrane such as a surfactant, wherein the first gas and the second gas are present in a molar ratio of from about 1:100 to about 1000:1, and wherein the first gas has a vapor pressure of at least about (760-x) mm Hg at 37 C., where x is the vapor pressure of the second gas at 37 C., and wherein the vapor pressure of each of the first and second gases is greater than about 75 mm Hg at 37 C.; also disclosed are methods for preparing microbubble compositions, including compositions that rapidly shrink from a first average diameter to a second average diameter less than about 75% of the first average diameter and are stabilized at the second average diameter; kits for preparing microbubbles; and methods for using such microbubbles as ultrasound contrast agents

Claims (30)

1 . An injectable ultrasound contrast agent comprising:

(a) a suspension of gas filled microbubbles or microballoons in a physiologically acceptable aqueous carrier comprising a membrane comprising a surfactant and a protein or glycoprotein and additives wherein:

(b) the gas is a gas mixture of at least two biocompatible gases A and B;

(c) gas B is present in an amount of between 50%-99% by volume;

(d) gas B has a water solubility of not more than about 0.5 mM at 25° C. and one atmosphere and an average molecular weight at least about 4 times that of gas A; and,

(e) the balance of the mixture is gas A.

2 . The injectable contrast agent of claim 1 wherein the aqueous carrier is water.

3 . The injectable contrast agent of claim 1 wherein gas B is perfluoropropane.

4 . The injectable contrast agent of claim 1 wherein gas B is selected from the group consisting of perfluoropropanes, perfluorobutanes, perfluorocyclobutanes, perfluoropentanes, perfluorocyclopentanes, perfluoro methylcyclobutanes, perfluorohexanes, perfluorocyclohexanes, perfluoro methyl cyclopentanes, perfluoro dimethyl cyclopentanes, perfluoro heptanes, perfluoro cycloheptanes, perfluoro cycloheptanes, perfluoromethyl cyclohexanes, perfluoro dimethyl cyclopentanes, perfluoro trimethyl cyclobutanes perfluoro triethylamines.

5 . The injectable contrast agent of claim 1 wherein gas B is selected from group consisting of perfluoropropanes, perfluorobutanes, perfluoropentanes, perfluorohexanes and perfluoro heptanes.

6 . The injectable contrast agent of claim 1 wherein gas A is selected from oxygen, nitrogen and carbon dioxide.

7 . The injectable contrast agent of claim 1 wherein gas A is air.

8 . The injectable contrast agent of claim 1 wherein at least one surfactant is a phospholipid.

9 . The injectable contrast agent of claim 1 wherein at least one surfactant comprises a mixture of phospholipids.

10 . An injectable ultrasound contrast agent comprising:

(a) a suspension of gas filled microbubbles or microballoons in a physiologically acceptable aqueous carrier comprising a surfactant comprised of at least one phospholipid and further comprising a protein or glycoprotein wherein:

(b) the gas is a gas mixture of at least two biocompatible gases A and B;

(c) gas B is present in an amount of between 0.5-50% by volume;

(d) gas B has a water solubility of not more than about 0.5 mM at 25° C. and one atmosphere and an average molecular weight at least about 4 times that of gas A; and,

(e) the balance of the mixture is gas A.

11 . The injectable contrast agent of claim 10 wherein the physiological aqueous carrier is water.

12 . The injectable contrast agent of claim 10 wherein gas B is perfluoropropane.

13 . The injectable contrast agent of claim 10 wherein gas B is selected from the group consisting of perfluoropropanes, perfluorobutanes, perfluorocyclobutanes, perfluoropentanes, perfluorocyclopentanes, perfluoro methylcyclobutanes, perfluorohexanes, perfluorocyclohexanes, perfluoro methyl cyclopentanes, perfluoro dimethyl cyclopentanes, perfluoro heptanes, perfluoro cycloheptanes, perfluoro perfluoro trimethyl cycloheptanes, perfluoromethyl cyclohexanes, perfluoro dimethyl cyclopentanes, cyclobutanes perfluoro triethylamines.

14 . The injectable contrast agent of claim 10 wherein gas B is selected from group consisting of perfluoropropanes, perfluorobutanes, perfluoropentanes, perfluorohexanes and perfluoroheptanes.

15 . The injectable contrast agent of claim 10 wherein gas A is selected from oxygen, nitrogen and carbon dioxide.

16 . The injectable contrast agent of claim 10 wherein gas A is air.

17 . The injectable contrast agent of claim 10 wherein said surfactant comprises a mixture of phospholipids.

18 . The injectable contrast agent of claim 10 wherein gas A and gas B are present in a molar ratio of between about 50:1 to about 1:1.

19 . The injectable contrast agent of claim 1 wherein gas A and gas B are present in a molar ratio of between about 1:1 to about 1:50.

20 . The injectable contrast agent of claim 10 further comprising additives and stabilizers.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2009
From: IMCOR PHARMACEUTICAL CO.
To: TARGESON, INC.
Reel/Frame 022248/0907 →
RELEASE OF SECURITY INTEREST Recorded Feb 13, 2009
From: IMCOR PHARMACEUTICAL CO.; OXFORD BIOSCIENCE PARTNERS IV L.P.; MRNA FUND II L.P; MI3 L.P.
To: IMCOR PHARMACEUTICAL CO.
Reel/Frame 022266/0174 →
RELEASE OF SECURITY INTEREST Recorded Jan 12, 2009
From: XMARK FUND, L.P.; XMARK FUND, LTD.
To: IMCOR PHARMACEUTICAL CO.
Reel/Frame 022086/0870 →